Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its holdings in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) by 24.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,150 shares of the company’s stock after selling 25,753 shares during the quarter. Dimensional Fund Advisors LP owned about 0.13% of Larimar Therapeutics worth $314,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LRMR. Renaissance Technologies LLC boosted its position in Larimar Therapeutics by 45.1% during the fourth quarter. Renaissance Technologies LLC now owns 513,542 shares of the company’s stock worth $1,987,000 after acquiring an additional 159,700 shares during the last quarter. XTX Topco Ltd boosted its holdings in Larimar Therapeutics by 316.3% in the 4th quarter. XTX Topco Ltd now owns 63,810 shares of the company’s stock valued at $247,000 after purchasing an additional 48,481 shares during the last quarter. Monimus Capital Management LP acquired a new position in Larimar Therapeutics in the 4th quarter valued at about $182,000. Barclays PLC boosted its holdings in Larimar Therapeutics by 321.2% in the 3rd quarter. Barclays PLC now owns 60,032 shares of the company’s stock valued at $393,000 after purchasing an additional 45,781 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in Larimar Therapeutics by 52.2% in the 4th quarter. Marshall Wace LLP now owns 110,304 shares of the company’s stock valued at $427,000 after purchasing an additional 37,810 shares during the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on LRMR shares. Truist Financial started coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 target price on the stock. Robert W. Baird decreased their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. HC Wainwright boosted their target price on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, March 25th. Citigroup reiterated a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Finally, Guggenheim reiterated a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $19.63.

Larimar Therapeutics Stock Performance

Shares of LRMR stock opened at $1.98 on Friday. The firm’s 50 day moving average price is $2.20 and its 200-day moving average price is $3.83. Larimar Therapeutics, Inc. has a one year low of $1.61 and a one year high of $11.20. The firm has a market cap of $126.78 million, a P/E ratio of -1.72 and a beta of 0.93.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). As a group, research analysts predict that Larimar Therapeutics, Inc. will post -1.15 EPS for the current fiscal year.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.